|
WO2021011345A1
|
|
Crystalline lorlatinib : fumaric acid and solid state form thereof
|
|
WO2020028448A1
|
|
Solid state forms of sugammadex sodium
|
|
WO2019209633A1
|
|
Solid state forms of lorlatinib and their preparation
|
|
WO2019014412A1
|
|
New crystalline polymorphs of bardoxolone methyl
|
|
WO2018013655A1
|
|
Solid state forms of crisaborole
|
|
US2020308141A1
|
|
Solid state forms of neratinib and salts thereof
|
|
EP3356327A1
|
|
Processes for the preparation of apremilast and intermediates thereof
|
|
WO2017035170A1
|
|
Solid state forms of cediranib maleate
|
|
HRP20120436A2
|
|
Imatinib mesylate capsule, method of production and its application
|
|
CA2795023A1
|
|
Crystal forms of o-desmethylvenlafaxine fumarate
|
|
US2011165202A1
|
|
Solid state forms of fosamprenavir calcium salt and processes for preparation thereof
|
|
EA022756B1
|
|
Crystalline forms of eltrombopag and use thereof
|
|
US2010240926A1
|
|
Process for preparing (r)-n-benzyl-2-(benyloxycarbonylamino)-3-methoxypropionamide
|
|
US2009298947A1
|
|
Polymorphic and amorphous forms of lacosamide and amorphous compositions
|
|
WO2009095634A1
|
|
Amorphous forms of retapamulin
|
|
WO2009092991A1
|
|
Process for preparing crystalline calcium mupirocin dihydrate
|
|
WO2009063171A1
|
|
Novel rotigotine salts
|
|
WO2009063170A1
|
|
Preparation of crystalline rotigotine base
|
|
WO2009053697A1
|
|
Polymorphic forms of ( s ) -rotigotine hydrochloride
|
|
WO2009056791A1
|
|
Processes for preparing pharmaceutical compounds
|
